What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Spliceosome Structure: Composition, Assembly, and Function

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to the Spliceosome

What is the Spliceosome?

The spliceosome is a large, dynamic ribonucleoprotein (RNP) machine that catalyzes the removal of introns from precursor messenger RNA (pre-mRNA) and the ligation of exons to form mature mRNA. This process, termed pre-mRNA splicing, is an essential step in eukaryotic gene expression. The spliceosome is composed of five small nuclear ribonucleoproteins (snRNPs)—U1, U2, U4, U5, and U6—and numerous non-snRNP protein factors. In human cells, the spliceosome contains over 150 distinct proteins and five small nuclear RNAs (snRNAs), making it one of the most complex macromolecular machines in the cell.

The Spliceosome Definition encompasses not a single static entity but a family of related complexes that assemble anew on each intron. The spliceosome is often described as a "ribozyme" because the catalytic core is formed by U6 snRNA, with U2 snRNA contributing to the active site architecture. However, unlike self-splicing introns, the spliceosome requires extensive protein machinery for assembly, conformational rearrangements, and regulation.

The overall structural organization of the spliceosome can be understood at three levels. First, the snRNP particles themselves have defined structures: each contains a snRNA, a set of seven Sm or Sm-like (LSm) proteins that form a ring around a conserved RNA sequence, and particle-specific proteins. Second, during assembly, these snRNPs and additional factors form a series of discrete complexes (E, A, B, Bact, B*, C, P, and ILS complexes) that can be biochemically isolated. Third, within the assembled spliceosome, the RNA components form a specific network of RNA-RNA base-pairing interactions that positions the two chemical steps of splicing.

The Splicing Reaction

Splicing occurs in two sequential transesterification reactions. In the first step, the 2′-hydroxyl of a conserved adenosine at the branch point (usually located 18–40 nucleotides upstream of the 3′ splice site) attacks the phosphodiester bond at the 5′ splice site. This produces a free 5′ exon with a 3′-hydroxyl and a lariat intermediate in which the intron is circularized through a 2′–5′ phosphodiester bond. In the second step, the 3′-hydroxyl of the 5′ exon attacks the phosphodiester bond at the 3′ splice site, ligating the two exons and releasing the lariat intron.

Both reactions occur in a magnesium-dependent manner within the spliceosome's active site. The chemistry is identical to that catalyzed by group II introns, and the structural similarity between U6 snRNA and domain V of group II introns strongly supports an evolutionary relationship. The spliceosome does not use ATP for the chemical steps themselves; instead, ATP is hydrolyzed by RNA-dependent ATPases (DExD/H-box helicases) that drive the conformational rearrangements required for assembly, activation, and disassembly.

Core Components: snRNPs and Proteins

Small Nuclear Ribonucleoproteins (snRNPs)

Each of the five snRNPs has a distinct composition and function. The Spliceosome Composed of these particles is summarized below.

U1 snRNP contains U1 snRNA (164 nucleotides in humans), the seven Sm proteins (B/B′, D1, D2, D3, E, F, and G), and three U1-specific proteins: U1-70K, U1-A, and U1-C. U1 snRNA base-pairs with the 5′ splice site through a conserved 11-nucleotide sequence at its 5′ end. U1-70K and U1-C stabilize this interaction and recruit other factors.

U2 snRNP contains U2 snRNA (187 nucleotides), the Sm proteins, and the U2-specific proteins U2-A′, U2-B″, and the SF3a and SF3b complexes. SF3b includes the proteins SF3b155, SF3b145, SF3b130, SF3b49, SF3b14a, and SF3b10. U2 snRNA base-pairs with the branch point sequence, and the SF3a/SF3b proteins protect this interaction and position the branch point adenosine for the first catalytic step.

U4/U6.U5 tri-snRNP is a pre-assembled complex containing three snRNAs. U4 snRNA (144 nucleotides) and U6 snRNA (106 nucleotides) are extensively base-paired to each other through two stem-loop regions. U5 snRNA (116 nucleotides) is also present. The tri-snRNP contains the Sm proteins on U4 and U5, LSm proteins (LSm2–LSm8) on U6, and at least 20 additional proteins, including Prp31, Prp3, Prp4, Prp6, and the U5-specific proteins Prp8, Brr2, Prp28, and Snu114. Prp8 is the largest protein in the spliceosome (~280 kDa in humans) and is a central scaffold that contacts the active site.

U6 snRNP exists in two forms: free U6 snRNP (with LSm proteins) and the U4/U6.U5 tri-snRNP. After U4 dissociates during activation, U6 remains in the catalytic core.

The following table summarizes the key features of each snRNP:

snRNP	snRNA length (human)	Core proteins	Primary function
U1	164 nt	Sm, U1-70K, U1-A, U1-C	5′ splice site recognition
U2	187 nt	Sm, U2-A′, U2-B″, SF3a, SF3b	Branch point recognition
U4	144 nt	Sm, Prp31, Prp3, Prp4	Chaperone for U6; dissociates during activation
U5	116 nt	Sm, Prp8, Brr2, Prp28, Snu114	Exon alignment and splice site positioning
U6	106 nt	LSm2–8, Prp24	Catalytic core; base-pairs with U2

Non-snRNP Splicing Factors

Beyond the snRNPs, the spliceosome requires numerous non-snRNP proteins. These include the SR (serine/arginine-rich) proteins, which promote splice site recognition; the hnRNP (heterogeneous nuclear ribonucleoprotein) proteins, which can antagonize splicing; and the protein factors that bridge snRNP interactions.

Key non-snRNP factors include:

SF1 (mammalian branch point binding protein, BBP in yeast): Binds the branch point sequence early in assembly.
U2AF (U2 auxiliary factor): A heterodimer of U2AF65 and U2AF35 that binds the polypyrimidine tract and 3′ splice site, respectively.
Prp19/CDC5 complex (NTC): A large complex that associates during activation and is required for stable U5/U6 interactions.
Residency factors: Proteins such as Prp2, Prp16, Prp22, and Prp43, which are DExD/H-box ATPases that drive conformational changes.

The Spliceosome Proteins list extends to over 150 distinct polypeptides in humans, many of which are metazoan-specific and play regulatory roles.

Structural Organization of the Spliceosome

The Active Site and Catalysis

The catalytic core of the spliceosome is formed by U6 snRNA, with critical contributions from U2 snRNA. The U6 snRNA folds into an intramolecular stem-loop (ISL) that coordinates two magnesium ions essential for catalysis. This arrangement is structurally analogous to the active site of group II introns, where domain V provides the metal-binding ligands.

The U2-U6 base-pairing interaction forms helix Ia and helix Ib, which bring the 5′ splice site and the branch point into proximity. The U6 ISL contains a conserved ACAGAGA box that base-pairs with the 5′ exon sequence near the 5′ splice site. The catalytic magnesium ions are coordinated by phosphates in the U6 ISL and by the U2-U6 helix.

Prp8, the largest spliceosomal protein, forms a scaffold around the active site. Prp8 contacts U5 snRNA, U6 snRNA, the 5′ splice site, and the branch point. It is thought to position the reactants and to stabilize the transition state. Mutations in Prp8 are associated with retinitis pigmentosa in humans, underscoring its functional importance.

RNA-RNA and RNA-Protein Interactions

The spliceosome's architecture is defined by an extensive network of RNA-RNA base-pairing interactions. These include:

U1 snRNA–5′ splice site: A 6–11 base-pair interaction that is the first recognition event.
U2 snRNA–branch point: A 6-nucleotide interaction that bulges out the branch point adenosine.
U4/U6 base-pairing: An extensive interaction that holds U6 in an inactive conformation prior to activation.
U6–5′ splice site: The ACAGAGA box of U6 base-pairs with the 5′ exon sequence.
U2-U6 helix I: A critical interaction that forms the catalytic core.
U5 snRNA–exon sequences: U5 snRNA base-pairs with the last few nucleotides of the 5′ exon and the first few nucleotides of the 3′ exon, aligning them for the second catalytic step.

RNA-protein interactions are equally important. The Sm/LSm protein rings bind the Sm site (a conserved sequence, AU4-6G, in U1, U2, U4, and U5 snRNAs) or the LSm site (in U6 snRNA). These rings stabilize the snRNAs and serve as platforms for protein recruitment. The SF3b complex in U2 snRNP wraps around the branch point interaction, protecting it from helicase action until the appropriate time.

Conformational Changes

The spliceosome undergoes dramatic conformational rearrangements during its functional cycle. These are driven by eight conserved DExD/H-box ATPases: Prp5, Prp28, UAP56/Sub2, Prp2, Prp8 (the Brr2 helicase is a separate protein), Prp16, Prp22, and Prp43. Each ATPase acts at a specific transition point.

Prp5 promotes U2 snRNP recruitment to the branch point.
UAP56/Sub2 promotes U2 snRNP stability and displaces SF1.
Prp28 destabilizes the U1–5′ splice site interaction, allowing U6 to take over.
Brr2 unwinds the U4/U6 duplex, releasing U4 and activating U6.
Prp2 remodels the Bact complex to form the catalytically active B* complex.
Prp16 promotes the first-to-second step transition by remodeling the active site.
Prp22 releases the mature mRNA after exon ligation.
Prp43 disassembles the spliceosome and recycles components.

These ATPases do not act as simple switches; they use ATP hydrolysis to remodel RNA-RNA and RNA-protein interactions in a directional manner. The Spliceosome Assembly process is therefore a series of energetically driven steps that ensure fidelity and order.

Assembly and Disassembly Cycle

Early Complexes (E, A)

Spliceosome assembly begins co-transcriptionally, while the pre-mRNA is still being synthesized by RNA polymerase II. The process follows a defined pathway:

E complex (commitment complex): U1 snRNP binds the 5′ splice site through base-pairing. SF1 binds the branch point, and U2AF65/U2AF35 bind the polypyrimidine tract and 3′ splice site. This complex is ATP-independent and commits the pre-mRNA to the splicing pathway.

A complex (pre-spliceosome): U2 snRNP joins, displacing SF1 and U2AF65. U2 snRNA base-pairs with the branch point, and the SF3a/SF3b proteins stabilize this interaction. ATP hydrolysis by Prp5 is required for stable U2 binding. The A complex contains U1, U2, and the pre-mRNA but lacks U4/U6.U5.

The E and A complexes are biochemically defined by their sedimentation coefficients (approximately 25S and 35S, respectively) and can be isolated by native gel electrophoresis or glycerol gradient centrifugation.

Activation and Catalytic Complexes (B, Bact, C)

B complex: The pre-assembled U4/U6.U5 tri-snRNP joins the A complex. This step requires the Prp31 protein and the GTPase Snu114. The B complex contains U1, U2, U4, U5, U6, and the NTC complex. At this stage, the spliceosome is catalytically inactive because U6 is still base-paired with U4.

Bact complex (activated): Prp28 and Brr2 act to destabilize U1–5′ splice site and U4/U6 interactions, respectively. U1 and U4 dissociate, and U6 base-pairs with U2 and the 5′ splice site. The NTC complex stabilizes these rearrangements. The Bact complex is now poised for catalysis but requires further remodeling.

**B* complex (catalytically activated)**: Prp2, with its cofactor Cwc22, remodels the Bact complex, releasing the SF3a/SF3b proteins from the branch point. This exposes the branch point adenosine for the first transesterification reaction.

C complex: The first catalytic step occurs, producing the free 5′ exon and lariat intermediate. The C complex then undergoes remodeling by Prp16, which checks the fidelity of the first step and rearranges the active site for the second step.

**C* complex (P complex)**: The second catalytic step occurs, ligating the exons and releasing the lariat intron. The P complex contains the mature mRNA and the excised intron.

Disassembly and Recycling

ILS complex (intron lariat spliceosome): After exon ligation, Prp22 releases the mature mRNA. The remaining complex, containing U2, U5, U6, the NTC, and the lariat intron, is the ILS complex.

Disassembly: Prp43, with its cofactors Ntr1 and Ntr2, disassembles the ILS complex. U6 snRNA is recycled by Prp24, which re-anneals U6 with U4 to reform the tri-snRNP. The lariat intron is debranched by the Dbr1 enzyme and degraded.

The entire cycle takes approximately 30–60 seconds per intron in vitro, though the rate in vivo is influenced by transcription, chromatin state, and regulatory factors. The Spliceosome Complex is thus a transient assembly that forms, acts, and disassembles for each intron.

Methods to Study Spliceosome Structure

Cryo-Electron Microscopy

Cryo-electron microscopy (cryo-EM) has revolutionized the study of spliceosome structure. Unlike X-ray crystallography, cryo-EM does not require crystalline samples and can capture large, flexible complexes in near-native conditions. The spliceosome is an ideal cryo-EM target because it is large (~1.5–2 MDa in the assembled state) and undergoes conformational changes that can be trapped by chemical or genetic means.

The general workflow involves:

Sample preparation: Spliceosomes are assembled in vitro using nuclear extracts or purified components, then stalled at specific stages using ATPase mutants, non-hydrolyzable ATP analogs, or antibodies against specific factors.
Grid preparation: Samples are applied to holey carbon grids and vitrified by rapid freezing in liquid ethane at approximately −180°C.
Data collection: Thousands of micrographs are collected on a transmission electron microscope equipped with a direct electron detector. Modern instruments can collect 1,000–3,000 movies per day.
Image processing: Individual particle images are aligned and classified using software such as RELION or cryoSPARC. This yields 3D reconstructions at resolutions of 3–5 Å, sufficient to build atomic models.

Cryo-EM structures have been determined for the yeast and human spliceosome at nearly every stage of the assembly pathway, including the A, B, Bact, B*, C, C*, P, and ILS complexes. These structures have revealed the precise arrangement of the active site, the path of the pre-mRNA, and the conformational changes that accompany each step.

Crosslinking and Mass Spectrometry

Chemical crosslinking combined with mass spectrometry (XL-MS) provides information about protein-protein and RNA-protein contacts in solution. In a typical experiment:

A crosslinking reagent such as disuccinimidyl suberate (DSS) is added to the spliceosome at a concentration of 0.5–2 mM.
The crosslinked complex is digested with proteases (e.g., trypsin) to produce peptides.
Mass spectrometry identifies crosslinked peptide pairs, revealing which residues are in close proximity (<30 Å).

For RNA-protein interactions, UV crosslinking at 254 nm followed by immunoprecipitation and sequencing (CLIP-seq) identifies the RNA sequences bound by specific proteins. This approach has been used to map the binding sites of Prp8, U2AF65, and SF3b155 on pre-mRNA.

Biochemical and Genetic Approaches

Biochemical assays remain essential for studying spliceosome function. The standard in vitro splicing assay uses a radiolabeled pre-mRNA substrate (e.g., adenovirus major late transcript) incubated with HeLa nuclear extract at 30°C for 60–90 minutes. Products are separated by denaturing polyacrylamide gel electrophoresis and visualized by autoradiography. This assay can be used to test the effects of mutations, antibodies, or depleted factors.

Native gel electrophoresis separates spliceosomal complexes by size and shape, allowing the visualization of E, A, B, and C complexes. Glycerol gradient sedimentation (10–30% glycerol, centrifuged at 40,000 rpm for 16 hours) provides a complementary separation method.

Genetic approaches in Saccharomyces cerevisiae have been particularly powerful. Temperature-sensitive mutations in splicing factors (e.g., prp2-1, prp16-1) allow conditional inactivation. Suppressor screens have identified interacting partners and have revealed the fidelity mechanisms of the spliceosome. For example, mutations in Prp8 that suppress prp16 defects identified the "fidelity triad" of Prp8, Prp16, and Prp22.

Spliceosome Dynamics and Regulation

Alternative Splicing

Alternative splicing allows a single gene to produce multiple mRNA isoforms by selecting different combinations of exons. It is estimated that >95% of human multi-exon genes undergo alternative splicing. The spliceosome is the executor of this regulation, but the decisions are made by regulatory proteins that influence splice site choice.

The major patterns of alternative splicing include:

Exon skipping: An exon is excluded from the mature mRNA.
Alternative 5′ splice site selection: Different 5′ splice sites are used.
Alternative 3′ splice site selection: Different 3′ splice sites are used.
Intron retention: An intron is retained in the mature mRNA.

The Spliceosome Splicing reaction itself is identical regardless of the regulatory outcome; the difference lies in which splice sites are selected and how the spliceosome is recruited.

Regulatory Elements and Factors

Splicing regulation is mediated by cis-acting RNA elements and trans-acting protein factors.

Cis-elements include:

Exonic splicing enhancers (ESEs): Purine-rich sequences that promote exon inclusion.
Exonic splicing silencers (ESSs): Sequences that repress exon inclusion.
Intronic splicing enhancers (ISEs) and intronic splicing silencers (ISSs): Similar elements within introns.

Trans-acting factors include:

SR proteins: Contain one or two RNA recognition motifs (RRMs) and an arginine/serine-rich (RS) domain. SR proteins bind ESEs and recruit U1 snRNP to the 5′ splice site and U2AF to the 3′ splice site. Examples include SRSF1 (ASF/SF2) and SRSF2 (SC35).
hnRNP proteins: Generally repress splicing by binding ESSs and blocking SR protein access. Examples include hnRNP A1 and PTB (polypyrimidine tract binding protein).
Tissue-specific factors: Proteins such as Nova, Fox-1/Fox-2, and Rbfox regulate splicing in specific cell types.

The balance between SR and hnRNP proteins at a given exon determines whether it is included or skipped. This is often described as a "splicing code" that integrates multiple inputs.

Regulation can also occur through the rate of spliceosome assembly. Slow assembly at weak splice sites allows time for regulatory factors to act. The spliceosome's proofreading mechanisms, mediated by Prp16 and Prp22, also contribute to regulation by rejecting suboptimal substrates.

Common Misconceptions and Pitfalls

snRNPs vs. Spliceosome

A frequent confusion is equating snRNPs with the spliceosome. The snRNPs are stable, pre-formed particles that exist in the nucleus independently of splicing. The spliceosome is the transient, fully assembled complex that forms on pre-mRNA. U1 snRNP, for example, exists as a free particle and also participates in other processes such as transcription initiation and mRNA 3′ end processing. The spliceosome is not a single entity but a series of complexes (E, A, B, Bact, C) that differ in composition.

Static vs. Dynamic

Students often imagine the spliceosome as a fixed machine with a defined structure. In reality, the spliceosome is one of the most dynamic macromolecular complexes known. It assembles de novo on each intron, undergoes at least eight major conformational rearrangements, and disassembles after each round of splicing. The U4/U6 interaction is entirely disrupted during activation, and U1 and U4 leave the complex entirely. The catalytic core itself is remodeled between the first and second steps.

Catalytic RNA vs. Protein

Another misconception is that the spliceosome is a protein enzyme with RNA substrates. In fact, the catalytic chemistry is performed by RNA: U6 snRNA coordinates the magnesium ions that catalyze both transesterification reactions. The proteins play essential structural and regulatory roles, but they do not directly catalyze the chemistry. This is why the spliceosome is considered a Spliceosome a Ribozyme. However, unlike self-splicing introns, the spliceosome cannot function without its protein components; it is a ribonucleoprotein enzyme, not a naked RNA catalyst.

Additional Pitfalls

Confusing the branch point with the 3′ splice site: The branch point is upstream of the 3′ splice site and is not the site of exon ligation.
Thinking ATP is used for catalysis: ATP is used for conformational rearrangements, not for the transesterification chemistry.
Assuming all introns are spliced by the same pathway: While the major spliceosome (U2-dependent) handles most introns, a minor spliceosome (U12-dependent) splices a small subset of introns using U11, U12, U4atac, U6atac, and U5.
Overlooking co-transcriptional splicing: Splicing often occurs while transcription is ongoing, and the two processes are functionally coupled.

Summary and Key Takeaways

The spliceosome is a remarkable example of a dynamic ribonucleoprotein machine. Its structure is not fixed but evolves through a series of defined complexes, each with a specific composition and function. The catalytic core is formed by U6 snRNA, with U2 snRNA providing essential structural support. Assembly is ordered and ATP-driven, ensuring that splice sites are recognized with high fidelity. Disassembly recycles the components for subsequent rounds of splicing.

Frequently Asked Questions

What is the spliceosome made of?

The spliceosome is composed of five snRNPs (U1, U2, U4, U5, and U6) and numerous non-snRNP proteins. Each snRNP contains a small nuclear RNA, a ring of seven Sm or LSm proteins, and particle-specific proteins. In humans, the assembled spliceosome contains over 150 distinct proteins. The Spliceosome Made of these components varies by stage: early complexes contain U1 and U2, while the catalytically active complexes contain U2, U5, and U6.

How does the spliceosome recognize intron-exon boundaries?

The spliceosome recognizes three conserved sequence elements: the 5′ splice site (consensus GU at the intron start), the branch point (containing an adenosine), and the 3′ splice site (consensus AG at the intron end). U1 snRNA base-pairs with the 5′ splice site, U2 snRNA base-pairs with the branch point, and U2AF binds the polypyrimidine tract and 3′ splice site. These interactions are reinforced by SR proteins and other factors.

Is the spliceosome a static or dynamic complex?

The spliceosome is highly dynamic. It assembles de novo on each intron, undergoes multiple ATP-dependent conformational rearrangements, and disassembles after catalysis. The U4/U6 interaction is disrupted during activation, and U1 and U4 leave the complex. The active site is remodeled between the first and second catalytic steps.

What is the role of ATP in splicing?

ATP is hydrolyzed by DExD/H-box RNA helicases to drive conformational changes. These include U2 snRNP recruitment (Prp5), U1 displacement (Prp28), U4/U6 unwinding (Brr2), catalytic activation (Prp2), first-to-second step transition (Prp16), mRNA release (Prp22), and complex disassembly (Prp43). ATP is not used for the transesterification chemistry itself.

How is the spliceosome structure studied?

The primary technique is cryo-electron microscopy, which has produced near-atomic resolution structures of spliceosomal complexes at multiple stages. Complementary methods include X-ray crystallography (for individual snRNPs), chemical crosslinking with mass spectrometry, native gel electrophoresis, glycerol gradient sedimentation, and genetic analysis in yeast.

What is the difference between snRNPs and the spliceosome?

snRNPs are stable, pre-formed particles that exist independently in the nucleus. The spliceosome is the transient, fully assembled complex that forms on pre-mRNA. snRNPs are components of the spliceosome, but the spliceosome also contains non-snRNP proteins and the pre-mRNA substrate.

Does the spliceosome catalyze splicing via RNA or protein?

The catalytic chemistry is performed by RNA, specifically U6 snRNA, which coordinates the magnesium ions required for both transesterification reactions. U2 snRNA contributes to the active site structure. Proteins play essential structural and regulatory roles but do not directly catalyze the chemistry. The spliceosome is therefore classified as a ribozyme, albeit one that requires proteins for function.

Key Takeaways

The spliceosome is a dynamic ribonucleoprotein machine that removes introns from pre-mRNA in two transesterification reactions.
It is composed of five snRNPs (U1, U2, U4, U5, U6) and over 150 proteins in humans.
The catalytic core is formed by U6 snRNA, with U2 snRNA providing structural support; the spliceosome is a ribozyme.
Assembly proceeds through defined complexes (E, A, B, Bact, B*, C, P, ILS) driven by eight DExD/H-box ATPases.
ATP hydrolysis powers conformational rearrangements, not the chemical steps of splicing.
The spliceosome assembles de novo on each intron and disassembles after catalysis, making it inherently dynamic.
Alternative splicing is regulated by cis-elements and trans-acting factors that influence splice site selection without altering the core splicing chemistry.